This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
LaFave, L.M. et al. Nat. Med. 21, 1344–1349 (2015).
Schoumacher, M. et al. Nat. Med. 22, 577–578 (2016).
Kim, K.H. & Roberts, C.W. Nat. Med. 22, 128–134 (2016).
Fong, C.Y. et al. Nature 525, 538–542 (2015).
Matatall, K.A. et al. BMC Cancer 13, 371 (2013).
Harbour, J.W. et al. Science 330, 1410–1413 (2010).
Campbell, J.E. et al. ACS Med. Chem. Lett. 6, 491–495 (2015).
Kim, K.H. et al. Nat. Med. 21, 1491–1496 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
LaFave, L., Béguelin, W., Koche, R. et al. Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nat Med 22, 578–579 (2016). https://doi.org/10.1038/nm.4094
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.4094
This article is cited by
-
Epigenetic modifiers: activities in renal cell carcinoma
Nature Reviews Urology (2018)
-
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy
Nature Medicine (2018)